Linker Engineering of Hybrid Triazole-Thiazolidine Antifungals Identifies a Promising Lead Against Drug-Resistant Candida Species
Pharmaceuticals · 10.08.2026 · 19 (8) · 1260
DOI: 10.3390/ph19081260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 10.08.2026. Verfasst von Alexander Yu Rudenko und 17 weiteren Autor:innen. Beteiligte Einrichtung: Belozersky Institute of Physico-Chemical Biology, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Background
The emergence of antifungal resistance and the limited number of clinically available antifungal drug classes necessitate the development of new agents with improved efficacy and safety. We investigated how linker architecture influences the antifungal activity and lead properties of hybrid triazole-thiazolidine derivatives.
Methods
A focused library of triazole-thiazolidine hybrids incorporating alkylamine, amide, cyclic amine, 2-hydroxypropyl, and thiazepane linkers was synthesized and characterized. Antifungal activity was evaluated against reference strains and clinical isolates of Candida spp., Aspergillus fumigatus, dermatophytes, and Cryptococcus neoformans. Structure–activity relationships were analyzed by molecular docking. Selected compounds were further assessed by SCRAPPY profiling, fluorescence microscopy, mammalian-cell cytotoxicity assays, acute oral toxicity studies, and evaluation of microsomal stability and interactions with human CYP450 isoforms.
Results
Linker architecture strongly influenced antifungal potency. Amide- and cyclic amine-containing hybrids were generally the most active, whereas simple alkylamide derivatives showed narrower activity profiles. Compound 28 emerged as the most promising lead, exhibiting sub-microgram MIC values against several Candida isolates, particularly C. parapsilosis, and retaining measurable activity against an azole-resistant C. albicans strain. Docking generated putative CYP51-binding models, while SCRAPPY profiling and fluorescence microscopy revealed an azole-like cellular response consistent with perturbation of sterol-associated homeostasis. Compound 28 was tolerated at 300 mg/kg in an acute oral study but showed concentration- and time-dependent cytotoxicity and rapid CYP3A4-mediated microsomal metabolism.
Conclusions
Systematic variation of linker architecture identified compound 28 as a promising exploratory antifungal lead. Further optimization should focus on improving metabolic stability and cytotoxicity, together with direct target validation, pharmacokinetic characterization, and in vivo efficacy studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Belozersky Institute of Physico-Chemical Biology, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia.
- Chemical Department, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia.
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya 16/10, 117997 Moscow, Russia.
- Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia.
- Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia.
- N.S. Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russia.
ORCID-Profile: Ratislav M Ozhiganov, Ekaterina A Guseva, Natalia E Grammatikova, Victoria A Bidiuk, Sofia S Mariasina, Vasiliy A Ivlev, Peter V Sergiev, Vladimir I Polshakov
Förderung
- Russian Science Foundation
Zitieren
APA
Rudenko, A. Y., Komarova, O. A., Simonov, A. Y., Ozhiganov, R. M., Averianov, D. A., Kuklich, S. R., Guseva, E. A., Sokolskaya, S. Y., Kuz'mina, L. G., Grammatikova, N. E., Kulko, A. B., Bidiuk, V. A., Mariasina, S. S., Ivlev, V. A., Sergiev, P. V., Polshakov, V. I., Mantsyzov, A. B., & Levshin, I. B. (2026). Linker Engineering of Hybrid Triazole-Thiazolidine Antifungals Identifies a Promising Lead Against Drug-Resistant Candida Species. Pharmaceuticals, 19(8), 1260. https://doi.org/10.3390/ph19081260
Vancouver
Rudenko AY, Komarova OA, Simonov AY, Ozhiganov RM, Averianov DA, Kuklich SR, et al. Linker Engineering of Hybrid Triazole-Thiazolidine Antifungals Identifies a Promising Lead Against Drug-Resistant Candida Species. Pharmaceuticals. 2026;19(8):1260. doi:10.3390/ph19081260
BibTeX
@article{Rudenko2026,
author = {Rudenko, Alexander Yu and Komarova, Olga A and Simonov, Alexander Yu and Ozhiganov, Ratislav M and Averianov, Dmitrii A and Kuklich, Sofiia R and Guseva, Ekaterina A and Sokolskaya, Sofya Y and Kuz'mina, Lyudmila G and Grammatikova, Natalia E and Kulko, Alexander B and Bidiuk, Victoria A and Mariasina, Sofia S and Ivlev, Vasiliy A and Sergiev, Peter V and Polshakov, Vladimir I and Mantsyzov, Alexey B and Levshin, Igor B},
title = {Linker Engineering of Hybrid Triazole-Thiazolidine Antifungals Identifies a Promising Lead Against Drug-Resistant Candida Species},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1260},
doi = {10.3390/ph19081260}
}
EUVIMED